New video just out on youtube for the presentation that Bill gave at the recent Sachs Neuroscience Innovation Forum (link below).
He seemed a bit rusty, but generally a good preso.
Couple of key points I took out of it....
- the final DSMB safety analysis will be “in a month or two”
- confident that the efficacy design is appropriate based on the first DSMB analysis
- full results reading out in “May/June”
- they’ve been approached by others for additional indications using xanamem
- current target market for mild Alzheimer’s is US$7.5B based on 1.5m patients. Bill alludes to the upside if you include Prodromol and At Risk markets which have numbers of 4m and 25m, respectively. Even penetrating only 10% of those markets would be massive given that there are almost 20 times more potential users than mild AD.
New video just out on youtube for the presentation that Bill...
Add ACW (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.3¢ |
Change
-0.001(4.17%) |
Mkt cap ! $70.90M | |||
| Open | High | Low | Value | Volume |
| 2.5¢ | 2.5¢ | 2.3¢ | $29.76K | 1.224M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 26 | 3353309 | 2.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.4¢ | 300000 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| ACW (ASX) Chart |